Dorota Hryniewicka – Firlej - Leading position in the market
ul. Żwirki i Wigury 16B
Pfizer Trading Polska Sp. z o.o.
ul. Żwirki i Wigury 16B
Kapitał zakładowy Pfizer Trading Polska Sp. z o.o. 11 050 000 zł NIP 521-33-28-885 Regon 140038400
DOROTA HRYNIEWIECKA-FIRLEJ, President of Pfizer Polska, talks to “Polish Market”.
PM: This year marks the 60th anniversary of Pfizer’s activity in Poland. It is an exceptional achievement. How would you assess those 60 years?
DHF: We are very proud of those 60 years on the Polish market. Looking at our business and the effects of our work from the perspective of so many years and so many changes, it is fair to say that we have achieved a lot. However, our success is not measured by the number of prizes and awards, or our leading position in the market. Above all, we measure our success by the number of human lives saved and the improved wellbeing of patients. For years, we have striven every day to give Polish patients access to the greatest developments in modern medicine.
Today, after 60 years on the Polish market, we are happy to say that we have registered more than 120 medicinal products. We are present in the most important therapeutic areas that are most significant for public health, with our originator drugs and personal treatment in oncology, solutions for patients with chronic autoimmune inflammatory diseases, rare diseases, and antibiotic therapy. We also ensure disease prevention for Polish patients by offering them a fantastic vaccine portfolio. Thanks to our wide experience, we have been able to build a strong market position.
However, our present position is due to our past work. We started from scratch – it is incredible that Pfizer started its business in Poland with single-person representation. At that time, the main pillar of our work was information activities aimed at hospitals and physicians, and the provision of breakthrough (at that time) medicines – antibiotics – to our patients.
The next years brought development. We gained strength step by step, building our market position with each subsequent merger. Thanks to innovative research, and thus new discoveries, especially in the area of antibiotics, vaccines, or life-saving solutions, we were able to offer our patients more groundbreaking therapies. This was due to our hard work, or rather the work of our team, because Pfizer means people. Today, the company has 450 employees, specialists, and experts responsible for research and development, production, education, promotion, and pharmacovigilance. The company is formed by a strong team of people who do their best, as they know that our efforts offer a real chance for a better quality of human life.
Pełna treść artykułu dostępna poniżej w formacje pdf.